

Premature Ejaculation Market - Industry Analysis, Size Trends and Forecast by Arizton Advisory & Intelligence

The global premature ejaculation (PE) market is expected to cross \$1.9 billion, growing impressively at a CAGR of 8.9% during the period 2016–2022.

CHICAGO, IL, UNITED STATES, November 16, 2017 /EINPresswire.com/ -- Innovus Pharma, Plethora Solutions, Absorption Pharmaceuticals and Allergan are the leading companies dominating the premature ejaculation market States a recent report by Arizton Advisory and Intelligence. The 138-page report provides a holistic view of the global premature ejaculation market, the companies involved in the market, and the factors driving its growth. The report also provides information about the latest trends that are likely to become strong market driving forces over the next five years. This report also provides the Porter's Five Forces analysis along with a description of each force and its impact on the market. Further, the report also provides complete value chain analysis of the global market.

View report: Premature Ejaculation -Global Outlook and Forecast 2017 - 2022



Premature Ejaculation Market: Key Vendor Analysis

The competitive landscape of the premature ejaculation market is concentrated with select players, which occupy a dominant market share. The rest of the market is composed of a plethora of manufacturers offering a generic version of off-label PE drugs.

Innovus Pharma Plethora Solutions Absorption Pharmaceuticals Allergan Other prominent vendors include Menarini, GlaxoSmithKline, Ixchelsis, Dong-A Pharmaceutical, NeuroHealing Pharmaceuticals.

Premature Ejaculation Market Dynamics

Emphasis on clinical progress of love hormone receptor antagonists to drive the market growth

Increase in prevalence of chronic diseases, low-effectiveness of nonpharmacological treatment, and a wide accessibility to premature ejaculation OTC drugs and generic off-label drugs are the prime factors that are going to



escalate the market growth during the forecast period. Furthermore, pharmaceutical advances in PE drug formulation technology, emphasis on clinical progress of love hormone receptor antagonists, and launch of premature ejaculation treatment awareness campaigns are the latest trends that are likely to positively impact the market. The report also provides the key restraints of the market.

٢٢

The topical PE drugs market is expected to witness growth at a higher pace than the oral PE drugs market" *Shravy, Sr. Ananlyst* Premature Ejaculation Market: Segmental Overview

The amide anesthetics segment is the fast-growing segment in terms of mechanism of action.

The oral drug segment to remain the dominant market in terms of route of administration. The topical PE drugs market is expected to witness growth at a higher pace than the oral

PE drugs market. However, the oral PE drugs market is likely to retain its market share until the end of the forecast period.

In terms of mechanism of action (MOA), the global PE market broad segments include SSRIs, PDE5 inhibitors, and amide anesthetics. In 2016, the SSRIs segment dominated the market. This segment is anticipated to retain its dominance till the end of forecast period. The amide anesthetics segment, which occupied low share in 2016, is anticipated to witness higher growth than the other drug MOAs segment during the period 2016-2022.

Route Administration (Topical therapies, Oral therapy)

Mechanism of Action (SSRI, PDE5 inhibitors, Ester/Amide anesthetics)

Premature Ejaculation Market: Geographical Analysis

North America to remain the largest market followed by Europe

The premature ejaculation market in North America is the largest due to high prevalent PE population. The US occupies approximately 90% of the PE market in North America due to the high population density and comparably higher utilization of off-label and OTC PE products. Similarly, the UK, Germany, France, Spain, and Italy are the leading markets for PE therapies in the European

region. The market in APAC is likely to witness the highest growth rate during the forecast period. A significant increase in PE incidence due to growing burden of chronic conditions, which, in turn, is associated with the high risk of PE occurrence is expected to boost the market growth in this region. The prevalence of PE in the Middle East countries and Latin America is estimated to be lowest than other regions. The market, however, is anticipated to witness a moderate growth rate in these regions.

Looking for more information? Request a free sample.

Related Reports

Sexual Wellness Market - Global Outlook and Forecast 2017 - 2022 https://www.arizton.com/reports/healthcare-lifesciences/sexual-wellness-market

About Arizton Advisory & Intelligence

Arizton – Advisory and Intelligence is an innovation and quality-driven firm, which offers cutting-edge research solutions to clients across the world. We excel in providing comprehensive market intelligence reports and advisory and consulting services.

Arizton has gained a paramount standpoint in the market research arena as it offers top of the line solutions to clients to assess market landscape and to finalize foolproof business strategies. We are committed to provide inclusive market research reports and consulting services to clients from diversified industries including –Consumer Goods & Retail Technology, Automotive and Mobility, Smart Tech, Healthcare and Lifesciences, Industrial Machinery, Chemicals and Materials, IT and Media, Logistics and Packaging

Arizton comprises a team of exuberant and well-experienced analysts who have mastered in generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.

Mail: enquiry@arizton.com Call: +1-312-465-7864

Jessica Arizton Advisory & Intelligence 3122352040 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.